Drug Profile


Alternative Names: CA-18C3; CV-18C3; Human IGG1 monoclonal antibody specific for human interleukin-1 alpha; Hutruo; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XBiotech
  • Developer Hellenic Institute for the Study of Sepsis; XBiotech
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Hidradenitis suppurativa; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
  • Phase I Haematological malignancies

Most Recent Events

  • 07 Jul 2017 Cedars-Sinai Medical Center, Ipsen and XBiotech plan a phase I trial for Cachexia (in patients with pancreatic cancer, Adjunctive therapy) in USA (NCT03207724)
  • 23 Jun 2017 XBiotech requests CHMP for re-examination of its opinion for MABp1 for Colorectal cancer
  • 12 Jun 2017 XBiotech terminates the phase III XCITE trial in Colorectal cancer in USA, United Kingdom, Netherlands, Poland, Hungary, Belgium, Czech Republic, Spain, Austria, and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top